Notably, GLYATL1 expression is positively regulated by estrogen receptor alpha signaling, however, independently of estrogen.<h4>Conclusions</h4>These findings reveal GLYATL1 as a metabolic and epigenetic mediator of endocrine therapy resistance, suggesting it as a potential target to overcome AI resistance in luminal breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.